CNS Protein changes name to Amarantus
This article was originally published in Scrip
CNS Protein Therapeutics, a private US biotechnology company, has changed its name to Amarantus Therapeutics and has appointed Martin Cleary CEO. The name change reflects Amarantus's new strategy to develop its first novel drug candidate, the growth factor AMRS001, for the treatment of Parkinson's disease and myocardial infarction. Mr Cleary, formerly president and CEO of vaccine company Juvaris BioTherapeutics, succeeds the company's co-founder Gerald Commissiong, who becomes chief business officer.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.